Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.
Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.
复制标题
DOI：
10.1097/iae.0b013e3182215ae9
复制
发表时间：
2012-04
期刊：
影响因子：
--
通讯作者：
Fishman GA
中科院分区：
文献类型：
--
作者：
Genead MA;McAnany JJ;Fishman GA
目的：探讨局部应用碳酸酐酶抑制剂对无脉络膜黄斑囊样水肿（CME）患者黄斑厚度和功能的影响。通过光谱域光学相干断层扫描（SD-OCT）观察到的两名CME无脉络膜患者接受了局部形式的碳酸酐酶抑制剂治疗。治疗前和治疗期间进行的检查包括：使用早期治疗糖尿病视网膜病变研究（ETDRS）图表测量最佳矫正视力（BCVA），使用简要介绍的光栅目标测量对比敏感度（光栅CS）和Pelli-Robson图（P-R CS），微视野（MP），2例接受2%多佐胺制剂治疗的无脉络膜症患者的黄斑厚度在SD-OCT时显著降低。OCT。治疗2个月后，在双眼中发现了这种减少。在另外3个月的相同治疗方案后，观察到黄斑厚度的更明显的减少。在ETDRS视力表上，两名研究患者至少有一只眼睛的视力有所改善，但其他视功能指标无临床显著变化。本研究显示了外用多佐胺治疗无脉络膜患者CME的潜在疗效。
To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema (CME). Two choroideremia patients with CME, observed by spectral-domain optical coherence tomography (SD-OCT), were treated with a topical form of carbonic anhydrase inhibitor. Examinations performed before and during treatment included: best corrected visual acuity (BCVA) by using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, contrast sensitivity measured with briefly presented grating targets (grating CS) and the Pelli-Robson chart (P-R CS), microperimetry (MP), and SD-OCT. The two choroideremia patients treated with dorzolamide 2% formulation had a noticeable reduction in macular thickness by SD-OCT. This reduction was found in both eyes after 2 months of treatment. After an additional 3 months of the same treatment regimen, a more noticeable reduction in macular thickness was observed. The two study patients had improvement of their visual acuity, in at least one eye, on ETDRS charts, but no clinically significant changes for the other measures of visual function. The present study shows the potential efficacy of topical dorzolamide for treating choroideremia patients with CME.